In studies of humans with type 2 diabetes, glycaemic control is generally better with tirzepatide than with selective GLP-1 RAs (dulaglutide [14], semaglutide [16]) coincident with a greater insulin response to glucose [50]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.